Compositions and Methods for Production of Exofucosylated Cells for Clinical Applications
Summary
Robert Sackstein filed US20260109950A1 on April 23, 2026, covering compositions and methods for detecting changes in cell-surface Type 2 terminal lactosamine expression levels and for enforcing stably expressed glycans on human cells using α(1,3)-fucosyltransferase family members. The application, filed September 16, 2025 under Application No. 19330402, describes glycoengineered CD44 glycosylated product (HCELL) that remains stable for at least 48 hours at 4°C with retained expression after cell cryopreservation. This is a patent application publication providing public notice of the filed application and establishing priority dates.
“The present disclosure provides, inter alia, compositions and methods for detecting changes in level of expression of cell-surface Type 2 terminal lactosamines on a population of cultured cells propagated under different conditions.”
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 256 changes logged to date.
What changed
This patent application publication makes public the existence of a filed application for compositions and methods relating to exofucosylated cell production. The application claims priority and is now available for public inspection, establishing a priority date of September 16, 2025. Parties interested in the technology should monitor prosecution status for final grant or abandonment, and conduct freedom-to-operate analysis before commercializing related products.
The publication provides notice to potential competitors and licensees about the existence of this intellectual property claim. Research institutions and biotechnology companies working in glycosylation or cell therapy may wish to review the claims when prosecution advances to determine whether their activities could infringe upon the patent if granted.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR PRODUCTION OF EXOFUCOSYLATED CELLS FOR CLINICAL APPLICATIONS
Application US20260109950A1 Kind: A1 Apr 23, 2026
Inventors
Robert Sackstein
Abstract
The present disclosure provides, inter alia, compositions and methods for detecting changes in level of expression of cell-surface Type 2 terminal lactosamines on a population of cultured cells propagated under different conditions. The disclosure also provides compositions and methods for enforcing stably expressed glycans on human cells. In certain embodiments, the compositions and/or methods utilize one or more members of the α(1,3)-fucosyltransferase family. In certain embodiments, glycoengineered CD44 glycosylated product (e.g. HCELL) is stable for at least 48 hours at 4° C., with retained expression after cell cryopreservation.
CPC Classifications
C12N 5/0662 C12Q 1/48 C12N 2500/34 C12N 2500/84 C12N 2501/724 G01N 2333/91091 G01N 2400/00
Filing Date
2025-09-16
Application No.
19330402
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.